[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertise Here
October 3, 2011
Volume 89, Number 40
p. 11

Drug Discovery: Expanded initiative will bridge Lilly’s internal, philanthropic R&D efforts

Ann M. Thayer

  • Print this article
  • Email the editor

Latest News

October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Eli Lilly & Co. is building on its Internet-enabled approach to innovation by integrating more ways to find and evaluate potential new drugs. The company hopes to both expand its pipeline of drug candidates and find compounds for philanthropic use.

Lilly’s new Open Innovation Drug Discovery platform links its two-year-old Phenotypic Drug Discovery Initiative (PD2) with new Target Drug Discovery (TargetD2) and multidrug-resistant tuberculosis (MDR-TB) components. Lilly wants the platform to be a route for outside scientists to advance their compounds in development.

Alan D. Palkowitz, Lilly’s vice president of discovery chemistry research and technologies, compares the approach to multiple superhighways that “connect scientists from all over the world with Lilly for the common goal of finding new treatments for diseases where patients are in need and looking for answers, such as cancer, diabetes, and MDR-TB.”

Lilly will continue to use PD2 to screen molecules submitted by outside scientists and identify potential drug candidates that act by novel mechanisms or pathways. The company has added TargetD2 to screen molecules for their interactions with known disease targets. Lilly hands over all results to participating scientists but gets first rights to negotiate collaborations or licenses on successful hits ( C&EN, March 7, page 26).

As a bridge to the nonprofit Lilly TB Drug Discovery Initiative, set up in 2003, Lilly will also test molecules for activity against MDR-TB. Members of the TB initiative include the Infectious Disease Research Institute and the National Institutes of Health.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!